GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Dividend-Payout-to-FFO

Equillium (FRA:0FY) Dividend-Payout-to-FFO


View and export this data going back to 2018. Start your Free Trial

What is Equillium Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Equillium Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.